Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Continuous Paravertebral Block With Ropivacaine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Research Network

Common Treatments

  • Continuous Paravertebral Block With Ropivacaine1
  • Continuous Paravertebral Block With Saline1
  • Patientcontrolled Analgesia With Sufentanil1

Active Sponsors

  • Huazhong University of Science and Technology1
  • Netherlands: Ministry of Health, Welfare and Sports1

Top Investigators

  • Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Activity Timeline